For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Keros Therapeutics Inc (NASDAQ: KROS) closed the day trading at $13.83 up 0.66% from the previous closing price of $13.74. In other words, the price has increased by $0.66 from its previous closing price. On the day, 0.66 million shares were traded. KROS stock price reached its highest trading level at $13.905 during the session, while it also had its lowest trading level at $13.6.
Ratios:
For a better understanding of KROS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.81 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.58. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Wedbush Downgraded its Outperform to Neutral on January 17, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 15 ’25 when Pontifax Management 4 G.P. (20 sold 4,787,331 shares for $17.75 per share. The transaction valued at 84,975,125 led to the insider holds 0 shares of the business.
ADAR1 Capital Management, LLC sold 5,389,264 shares of KROS for $95,659,436 on Oct 15 ’25. The 10% Owner now owns 0 shares after completing the transaction at $17.75 per share. On Sep 12 ’25, another insider, Rovaldi Christopher, who serves as the Affiliate of the company, bought 85,306 shares for $15.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 561711232 and an Enterprise Value of -110549824. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 44.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 28.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.41 while its Price-to-Book (P/B) ratio in mrq is 0.79. Its current Enterprise Value per Revenue stands at -0.475 whereas that against EBITDA is -66.118.
Stock Price History:
The Beta on a monthly basis for KROS is 1.15, which has changed by -0.77064675 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is -9.32%, while the 200-Day Moving Average is calculated to be 2.68%.
Shares Statistics:
Over the past 3-months, KROS traded about 547.88K shares per day on average, while over the past 10 days, KROS traded about 1186650 shares per day. A total of 40.62M shares are outstanding, with a floating share count of 33.91M. Insiders hold about 16.50% of the company’s shares, while institutions hold 74.38% stake in the company. Shares short for KROS as of 1759190400 were 3867988 with a Short Ratio of 7.06, compared to 1756425600 on 4501318. Therefore, it implies a Short% of Shares Outstanding of 3867988 and a Short% of Float of 14.92.
Earnings Estimates
A comprehensive evaluation of Keros Therapeutics Inc (KROS) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.29 and low estimates of -$1.63.
Analysts are recommending an EPS of between $2.46 and -$0.21 for the fiscal current year, implying an average EPS of $1.0. EPS for the following year is -$4.01, with 8.0 analysts recommending between -$0.75 and -$5.81.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $250M, while the lowest revenue estimate was $220M, resulting in an average revenue estimate of $235.19M. In the same quarter a year ago, actual revenue was $3.55M
